anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Spontaneous corneal clearance after Descemetorhexis without keratoplasty (DWEK) has been documented in several previous trials. One of the largest cohorts at Massachusetts Eye and Ear Infirmary demonstrated spontaneous corneal clearance in about 82% of cases but mean time to clearance was approximately three months after the procedure. During this time period, patients have significantly reduced central vision. Furthermore, some patients fail to have corneal clearance even eight months after DWEK and have to undergo Descemet membrane endothelial keratoplasty (DMEK) to achieve corneal clearance. A recent international case report has documents that the addition of a rho kinase inhibitor, Ripasudil, to two eyes that failed to clear by two to three months after DWEK resulted in corneal clearance within two weeks after the addition of Ripasudil. This finding indicates the possibility that a rho kinase inhibitor can be used to speed corneal clearance after purposeful Descemetorhexis. The only FDA approved rho kinase inhibitor eye drop currently available is Netarsudil, approved in December of 2017 for use in ocular hypertension and primary open angle glaucoma. Investigating whether Netarsudil can speed corneal clearance after DWEK is truly importance as the potential to expand patient eligibility for DWEK is significant. Both patients that had previously not wanted to wait approximately three months after the procedure for corneal clearance as well as patients with lower mid-peripheral endothelial cell counts may now be eligible for a procedure to treat corneal endothelial dysfunction without a corneal transplant. This would reduce risks for corneal transplant rejection and failure, reduce need for long-term steroid eye drop use, and reduce need for frequent corneal screenings to ensure transplant health.

The current study aims to investigate whether the off-label use of Netarsudil can improve corneal clearance after DWEK in Fuchs endothelial dystrophy patients.
ARTEMIS is a prospective, cluster-randomized clinical trial that will evaluate whether patient copayment elimination significantly influences antiplatelet therapy selection and long-term adherence, as well as patient outcomes and overall cost of care after acute myocardial infarction. Approximately 11,000 patients with ST-elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) will be enrolled at the approximately 300 hospitals in this study. Study sites selected for ARTEMIS will be geographically diverse, and will represent a diversity of hospital types and capabilities (e.g., teaching hospital, community hospital, etc). After institutional review board (IRB) approval of the study, each hospital will be randomized into either the intervention arm or the control arm. Hospitals randomized to the intervention arm will have the opportunity to offer enrolled patients either clopidogrel (generic P2Y12 receptor inhibitor option) or ticagrelor (brand P2Y12 receptor inhibitor option) without patient contribution to copayment in the next 12 months after the index MI discharge. Hospitals in the control arm will provide care per usual clinical routine. Notably, for both intervention and control arms, all patient management decisions (including the choice of antiplatelet therapy) are completely at the discretion of the care providers. Duration of antiplatelet therapy will also be at the discretion of care providers. All enrolled patients will be followed up to 15 months after index MI discharge to collect data on longitudinal treatment patterns and outcomes. Primary and secondary endpoints will be assessed at 12 months. An additional three months of follow up will assess for antiplatelet persistence and clinical events after discontinuation of the copayment intervention. Centralized follow-up will be conducted every 3 months via telephone or web-based contact.
Tai Chi Easy: TCE is a standardized protocol used in several prior studies. TCE has been manualized and has a formal training program for instructors. The protocol is taught as a series of repeated and simple-to-learn movements. Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
PROBLEM TO BE SOLVED: To obtain a make-up cosmetic capable of improving skin conditions by imparting the skin with natural luster and transparency while toning the skin texture beautifully. SOLUTION: This make-up cosmetic contains 1.0 to 30.0wt.% of powder with irregular reflection to light and 0.05 to 15.0wt.% of powder with specular reflection to light; the weight ratio of the powder with specular reflection to the powder with irregular reflection is set to fall within the range of 0.01 to 5. The term 'powder with specular reflection' here is defined as follows. Powder is coated in an amount of 10mg/cm<2> on a 5cm×5cm transparent and double- sided pressure-sensitive adhesive tape pasted on a white smooth plate. Light is irradiated on the plate surface at the incident angle of 45 deg. and intensities of the reflected lights at the reflection angles of 0 deg. and 45 deg. respectively are measured.  Specular reflection is where the ratio of the intensity of the light reflected at the angle of 45 deg. to that at the angle of 0 deg. is >=1.2, while irregular reflection is where the ratio is <=1.1.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to diol-containing derivatives of quinoline of the general formula (I)   where R 1  means hydrogen or halogen atom but preferably fluorine or chlorine atom; m = 0, 1 or 2. Indicated compounds are synthesized by interaction of amine of the formula (II)   with compound of the formula (III)  . Compounds of the formula (I) show antagonistic activity and therefore they can be used as the pharmaceutical preparation in medicine. Invention relates to method of inhibition of specific contraction of smooth muscle also. EFFECT: improved method of synthesis, valuable medicinal properties. 8 cl, 3 tbl, 9 ex
Fenofibrate tablet, USP are a lipid regulating agent available as tablets for oral administration. Each tablet contains 54 mg or 160 mg of fenofibrate, USP. The chemical name for fenofibrate is 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester with the following structural formula:

The empirical formula is C 20H 21O 4Cl and the molecular weight is 360.83; fenofibrate, USP is insoluble in water. The melting point is 79 to 82°C. Fenofibrate, USP is a white or almost white, crystalline powder which is stable under ordinary conditions. 

Each 54 mg of fenofibrate tablet, USP contains the following inactive ingredients: Microcrystalline cellulose, colloidal silicon dioxide, crospovidone, lactose monohydrate, povidone, sodium lauryl sulfate, sodium stearyl fumarate, opadry AMB yellow powder. The opadry AMB yellow powder contains lecithin, polyvinyl alcohol, talc, titanium dioxide, D&C yellow #10 aluminum lake, FD & C blue #2/indigo carmine aluminum lake, FD & C yellow #6/sunset yellow FCF aluminum lake and xanthan gum. 

Each 160 mg of fenofibrate tablet, USP contains the following inactive ingredients: Microcrystalline cellulose, colloidal silicon dioxide, crospovidone, lactose monohydrate, povidone, sodium lauryl sulfate, sodium stearyl fumarate, opadry AMB white powder. The Opadry AMB white powder contains lecithin, polyvinyl alcohol, talc, titanium dioxide and xanthan gum.

Fenofibrate tablets, USP meets USP Dissolution Test 3.
Participants randomized to the gabapentin arm begin on a dose of 300 mg daily (300 mg qd). In week 2, participants will take 300 mg of gabapentin three times daily. In week 3 the dose will be titrated up to 1800 mg daily (300 mg+300 mg tid) will remain on the dose until week 8, when they will be tapered back down to 900 mg daily (300 mg tid). In week 8, in days 1-4 participants will take 1800 mg daily (300 mg+300 mg tid); in days 5-7, participants will take 900 mg daily (300 mg of gabapentin three times daily).
A method of combating a somatosensory disorder in a subject, comprising administering to the subject an effective amount of a composition comprising bupranolol and/or pharmaceutically acceptable derivative(s) thereof. Compositions useful for such administration are described, including salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine, in which such salt, ester, solvate, etc. compound is in enantiomeric excess or homoenantiomeric in the R isomer thereof, or is formulated with racemic mixtures of the R and S stereoisomers of the salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine. Combination therapy compositions of opioid receptor agonists and such compounds are also described. A method is disclosed of referential genotypic screening of candidate subjects in connection with therapeutic intervention using the compositions of the disclosure to combat the somatosensory disorder.
A single dose of PEG is given first, followed 1 week later by PEB + BOC 100 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
BACKGROUND: Thoracic esophageal cancer resection through the neck approach has recently been reported as mediastinoscopic surgery. We present the first report of a new minimally invasive technique for thoracic esophageal cancer: robot-assisted transcervical esophagectomy with a bilateral cervical approach.
METHODS: Ten cases of robot-assisted bilateral transcervical esophagectomy performed at the National Cancer Center Hospital East, Japan, from February 2023 to August 2023 were reviewed. The short-term surgical outcomes were presented, and the feasibility and efficacy of this procedure were discussed.
RESULTS: The mean operation time for the cervical procedure was 184.2 ± 23.6 min. The total time for the whole procedure was 472.7 ± 28.4 min, and total intraoperative blood loss was 162.2 ± 40.0 ml. Among the 10 cases, one patient developed recurrent nerve paralysis, one patient developed pulmonary complications, and no patients developed postoperative pneumonia. The median postoperative hospital stay was 22 (range: 12-43) days. No patients developed severe postoperative surgical complications, which were graded as Clavien-Dindo ≥ III. The total number of surgically harvested mediastinal lymph nodes was 37.2 ± 11.2.
CONCLUSIONS: Robot-assisted bilateral transcervical esophagectomy, a novel procedure for thoracic esophageal cancer, was safe and feasible. Using this procedure, the incidence of recurrent nerve palsy, which is a problem with transcervical esophagectomy and mediastinoscopic esophagectomy, is expected to decrease.
FIELD: medicine, biology. SUBSTANCE: biologically active preparation has a matrix and particles of ultradispersed powders at metastable state. Antitumor properties are provided by the presence of ultradispersed powders of iron and/or copper, and/or silver, and/or platinum. Bactericidal properties are provided by the presence of ultradispersed powders of copper and/or iron, and/or silver, and/or zinc. Biostimulating properties are provided by the presence of ultradispersed powders of iron and/or copper, and/or silver, and/or platinum at microdoses no causing toxic and cytodestructive effect on normal cells and tissues of body. Ultradispersed powders containing ferromagnetic component are used for tropism enhancement and iron oxide and/or aluminium oxide are used for sorption property increase. Biologically active preparation can be used for treatment of wounds, burns, tumors and metabolic processes correction. EFFECT: enhanced activity of preparation. 6 cl, 4 tbl
At Catalina Research Institute, a subset of subjects who received placebo in the single-blind Cohorts 1 and 2 at that site will be recruited to an open label cross over Cohort 3 where they will receive the study drug (TVB-2640 tablet) orally every day for 12-week treatment period. Additional patients from outside the pool of previous placebo subjects may be needed to meet the enrollment target.
PURPOSE:To obtain a low-sensitizing flavor component, without deteriorating the characteristics of the flavor, by contacting a flavor component containing a sensitizing substance which causes allergic raction to the skin with an aqueous solution containing proteins under weakly alkaline condition under stirring, and recovering the flavor component. CONSTITUTION:A flavor component containing a sensitizing substance such as cinnamic aldehyde, etc. is mixed with an aqueous solution containing a protein, e.g. bovine or human serum albumin, horse or human gamma-globulin, egg albumin, milk casein sodium, etc. under weakly alkaline condition, especially at 7.5-8.5pH, and stirred preferably at 20-50 deg.C, especially about 37 deg.C. The weight ratio of the flavor component to the aqueous solution is usually 0.5- 3 to 100. The flavor component free from the sensitizing substance is recovered from the mixture to obtain a low-sensitizing flavor component which can be safely applied to the human body without causing sensitizing reaction, and has high commercial value.
In the first 2 weeks, sessions were held with all patients once a week. In these two sessions, the basic information of scoliosis were explained to both groups. Postural corrections were explained to the patients, including the basic elements of clinical pilates. It was stated that they should breathe towards the concave side of the major curve (weak breathing zone) during exercises and postural corrections.In the Pilates-based exercise program, sessions are planned as 10 minutes of warm-up, 10 minutes of cool-down and 40 minutes of scoliosis-specific pilates-based exercises for approximately 1 hour. Total number of exercises is 12 for one session.The patients in the control group continued the exercise program every day of the week for 12 weeks. Exercise lists were sent to the patients in the form of electronic booklets via an electronic communication application every week, and their continuity with the exercise program was checked with the diaries they were asked to fill in.
FIELD: medicine, virology. SUBSTANCE: invention relates to method for preparing hepatitis B surface antigen from recombinant yeast cells Hansenula polymorpha and can be used in biotechnology for preparing vaccine against hepatitis B. Method involves culturing recombinant yeast cells, disruption of cells in buffer containing chaotropic agent, addition of surface-active substance to cell homogenate, centrifugation of cell homogenate followed by hydrophobic chromatography and ultracentrifugation in potassium bromide density gradient, gel-filtration of fraction containing surface-active antigen. Hydrophobic chromatography is carried out in buffer containing 8-14% of ethanol followed by washing out with the same buffer at temperature 30 C and elution with the same buffer at temperature 40-42 C and gelfiltration is carried out on copolymer carrier. The preparation of surface antigen rHBs obtained from recombinant yeast cells Hansenula polymorpha is used for preparing vaccines for immunization against hepatitis B. EFFECT: improved method for preparing hepatitis B virus surface antigen. 2 cl, 2 tbl
Patients will be instructed to apply every 2 hours (8 times/day). The currently used bottle will be required to store at 4 C for 24 hours, and the remaining bottles at -20 C in a freezer until day of use.
The immune checkpoint receptor, programmed cell death 1 (PD-1, encoded by PDCD1), mediates the immune escape of cancer, but whether PD-1 splicing isoforms contribute to this process is still unclear. Here, we identify an alternative splicing isoform of human PD-1, which carries a 28-base pairs extension retained from 5' region of intron 2 (PD-1^28), is expressed in peripheral T cells and tumor infiltrating lymphocytes. PD-1^28 expression is induced on T cells upon activation and is regulated by an RNA binding protein, TAF15. Functionally, PD-1^28 inhibits T cell proliferation, cytokine production, and tumor cell killing in vitro. In vivo, T cell-specific exogenous expression of PD-1^28 promotes tumor growth in both a syngeneic mouse tumor model and humanized NOG mice inoculated with human lung cancer cells. Our study thus demonstrates that PD-1^28 functions as an immune checkpoint, and may contribute to resistance to immune checkpoint blockade therapy.
Depression and obesity are prevalent disorders with significant public health implications. In this study, we used a high-fat diet (HFD)-induced obese mouse model to investigate the mechanism underlying HFD-induced depression-like behaviors. HFD-induced obese mice exhibited depression-like behaviors and a reduction in hippocampus volume, which were reversed by treatment with an indoleamine 2,3-dioxygenase (IDO) inhibitor 1-methyltryptophan (1-MT). Interestingly, no changes in IDO levels were observed post-1-MT treatment, suggesting that other mechanisms may be involved in the anti-depressive effect of 1-MT. We further conducted RNA sequencing analysis to clarify the potential underlying mechanism of the anti-depressive effect of 1-MT in HFD-induced depressive mice and found a significant enrichment of shared differential genes in the extracellular matrix (ECM) organization pathway between the 1-MT-treated and untreated HFD-induced depressive mice. Therefore, we hypothesized that changes in ECM play a crucial role in the anti-depressive effect of 1-MT. To this end, we investigated perineuronal nets (PNNs), which are ECM assemblies that preferentially ensheath parvalbumin (PV)-positive interneurons and are involved in many abnormalities. We found that HFD is associated with excessive accumulation of PV-positive neurons and upregulation of PNNs, affecting synaptic transmission in PV-positive neurons and leading to glutamate-gamma-aminobutyric acid imbalances in the hippocampus. The 1-MT effectively reversed these changes, highlighting a PNN-related mechanism by which 1-MT exerts its anti-depressive effect.
FIELD: medicinal industry, medicine, infectious diseases. SUBSTANCE: invention relates to method for preparing preparation used for active immunization against tularemia. Invention developed method for preparing the preparation for active immunization against tularemia that provides protection of highly sensitive animals in infection with highly virulent strains of F. tularensis being both in parenteral and oral method of immunization. The preparation is prepared from cells of vaccine and virulent strains by fractionation of cells preliminary disrupted by hydrodynamic effect. Invention provides the enhancement of immunogenicity, elimination of adverse effects in using in vivo, enhancement of safety and reducing cost in preparing prophylactic preparation. EFFECT: improved preparing method, valuable medicinal properties of preparation. 7 cl, 5 ex
PCT No. PCT/EP90/01172 Sec. 371 Date Mar. 12, 1992 Sec. 102(e) Date Mar. 12, 1992 PCT Filed Jul. 17, 1990 PCT Pub. No. WO91/01335 PCT Pub. Date Feb. 7, 1991.The present invention provides modified IgG3 containing human constant regions which has a shorter total-hinge region compared with normal human IgG3. Also described is a method for assaying an antibody against a specific antigen or hapten for its effectiveness in complement activation in an animal species, wherein the antibody is contacted with the immobilized antigen or hapten to form an immobilized antibody/antigen or hapten complex which is then contacted with complement from the relevant animal species, followed by assay of components of the complement complex thereby formed; whereby the extent and nature of complement activation by the antibody in the sample may be determined.
NEW MATERIAL:The compound of formula I (R is lower alkyl). EXAMPLE:4-(1-Methyl-cis-4-tert-butylcyclohexyloxy)aniline. USE:A remedy for hyperlipemia and an intermediate raw material of N-[4-(1-substituted-4-tert-butylcyclohexyloxy)phenyl]-alpha-amino acid compound having lipid level lowering activity. It has excellent activity to lower the lipid level and remarkably increase the high-density lipoprotein in blood. PROCESS:The compound of formula I can be prepared by reacting the compound of formula II with the compound of formula IV (X is halogen) in the presence of a strong base such as NaH in a solvent at room temperature - the boiling point of the solvent for 1-10hr, and reducing the nitro group of the resultant compound of formula III e.g. by catalytic reduction, etc.
Plants which contains alkaloids coexisting with alkaloids of berberine type or berberine series, or a plant except Japanese barberrys (Berberis thunbergii) which contains the alkaloids and the leaves of Japanese barberry are treated for removal of fat and tar, and extracted with a polar solvent. The extract is treated with a soln. of alkali metal dihydrogen phosphate and a soln. of phosphoric acid or organic acid, and then condensed. The condensate is then neutralised or slightly alkalised with a soln. of dialkali metal hydrogen phosphate or alkali metal phosphate (when dipotassium hydrogen phosphate is used in the first stage and disodium hydrogen phosphate used in the second stage, Ohbaku (Phellodendron amurense) is excluded). Water is removed, and the residue is extracted with a polar solvent. Removal of the solvent by distillation yields the anti-Eumycetes agent.
Patients receive peginterferon alfa-2b subcutaneously (SC) weekly for 6 weeks. Treatment may repeat every 6 weeks for up to 18 courses in the absence of disease progression or unacceptable toxicity.
The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period will be performed 5-7 days after the scheduled proximal Roux-en-Y gastric bypass surgery. A sampling of a tissue specimen from the jejunum will be collected during the operation.
The importance of hemoglobin (Hgb) as a novel prognostic biomarker in predicting clinical features of cancers has been the subject of intense interest. Anemia is common in various types of cancer including breast cancer (BC) and is considered to be attributed to tumoral hypoxia. Cancer microenvironments are hypoxic compared with normal tissues, and this hypoxia is associated with Hgb concentration. Recent preclinical documents propose a direct or indirect correlation of intratumoral hypoxia, specifically along with acidity, with Hgb concentration and anemia. Analysis of the prognostic value of Hgb in BC patients has demonstrated increased hypoxia in the intratumoral environment. A great number of studies demonstrated that lower concentrations of Hgb before or during common cancer treatments, such as radiation and chemotherapy, is an essential risk factor for poor prognostic and survival, as well as low quality of life in BC patients. This data suggests a potential correlation between anemia and hypoxia in BC. While low Hgb levels are detrimental to BC invasion and survival, identification of a distinct and exact threshold for low Hgb concentration is challenging and inaccurate. The optimal thresholds for Hgb and partial pressure of oxygen (pO2) vary based on different factors including age, gender, therapeutic approaches, and tumor types. While necessitating further investigations, understanding the correlation of Hgb levels with tumoral hypoxia and oxygenation could improve exploring strategies to overcome radio-chemotherapy related anemia in BC patients. This review highlights the collective association of Hgb concentration and hypoxia condition in BC progression.